Free Trial

Candel Therapeutics (NASDAQ:CADL) Shares Up 2.5% - Should You Buy?

Candel Therapeutics logo with Medical background

Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) shot up 2.5% on Wednesday . The stock traded as high as $5.43 and last traded at $5.33. 217,298 shares changed hands during trading, a decline of 88% from the average session volume of 1,860,414 shares. The stock had previously closed at $5.20.

Candel Therapeutics Stock Down 2.6 %

The company has a market cap of $166.52 million, a P/E ratio of -3.08 and a beta of -0.88. The business's 50 day moving average price is $6.33 and its 200-day moving average price is $6.86. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.62 and a quick ratio of 1.62.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.74) EPS for the quarter. On average, analysts anticipate that Candel Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of Candel Therapeutics stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $6.02, for a total value of $90,300.00. Following the completion of the sale, the insider now directly owns 929,873 shares in the company, valued at $5,597,835.46. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders have sold 31,800 shares of company stock valued at $193,380. 41.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Candel Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Point72 DIFC Ltd bought a new position in Candel Therapeutics during the second quarter worth about $31,000. Rhumbline Advisers bought a new position in Candel Therapeutics during the second quarter worth about $143,000. Cubist Systematic Strategies LLC bought a new position in Candel Therapeutics during the second quarter worth about $162,000. Finally, Bank of New York Mellon Corp bought a new stake in Candel Therapeutics during the 2nd quarter worth approximately $338,000. 13.93% of the stock is owned by institutional investors and hedge funds.

Candel Therapeutics Company Profile

(Get Free Report)

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.

Read More

Should you invest $1,000 in Candel Therapeutics right now?

Before you consider Candel Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.

While Candel Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Can Blackwell Propel the Stock to $200+ in 2025?
These Top Stocks in 2024 Will Continue to be Big Winners in 2025
’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines